Psychemedics (PMD) 19.73 $PMD
39.3% Return Seen to Date on SmarTrend Psychemedics Call (PMD)
Comtex SmarTrend(R) - Wed Sep 21, 1:05PM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ
MD) on July 8th, 2016 at $14.46. In approximately 3 months, Psychemedics has returned 39.35% as of today's recent price of $20.15.
PMD: 19.73 (+0.09)
Uptrend Call Working As Psychemedics Stock Rises 37.9% (PMD)
Comtex SmarTrend(R) - Wed Sep 14, 12:44AM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ MD) on July 8th, 2016 at $14.46. In approximately 2 months, Psychemedics has returned 37.90% as of today's recent price of $19.94.
PMD: 19.73 (+0.09)
Psychemedics Corporation Earns Prestigious Recognition for Superior Customer Service
PR Newswire - Tue Sep 13, 4:24PM CDT
Psychemedics Corporation (NASDAQ: PMD), the world's leading and largest hair analysis drug testing company, announced that it has been certified as a Center of Excellence by BenchmarkPortal. The Center of Excellence recognition is one of the most prestigious awards in the customer service and support industry.
PMD: 19.73 (+0.09)
Psychemedics Up 45.2% Since SmarTrend Uptrend Call (PMD)
Comtex SmarTrend(R) - Tue Aug 30, 12:26AM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ MD) on July 8th, 2016 at $14.46. In approximately 2 months, Psychemedics has returned 45.23% as of today's recent price of $21.00.
PMD: 19.73 (+0.09)
48.6% Return Seen to Date on SmarTrend Psychemedics Call (PMD)
Comtex SmarTrend(R) - Mon Aug 22, 12:55PM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ MD) on July 8th, 2016 at $14.46. In approximately 2 month, Psychemedics has returned 48.62% as of today's recent price of $21.49.
PMD: 19.73 (+0.09)
Psychemedics Has Returned 43.3% Since SmarTrend Recommendation (PMD)
Comtex SmarTrend(R) - Fri Aug 05, 12:49AM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ MD) on July 8th, 2016 at $14.46. In approximately 4 weeks, Psychemedics has returned 43.29% as of today's recent price of $20.72.
PMD: 19.73 (+0.09)
Psychemedics Up 24.6% Since SmarTrend Uptrend Call (PMD)
Comtex SmarTrend(R) - Thu Jul 28, 1:38PM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ MD) on July 8th, 2016 at $14.46. In approximately 3 weeks, Psychemedics has returned 24.55% as of today's recent price of $18.01.
PMD: 19.73 (+0.09)
Shares of PMD Up 27.5% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue May 17, 12:49AM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ MD) on February 1st, 2016 at $10.20. In approximately 4 months, Psychemedics has returned 27.45% as of today's recent price of $13.00.
PMD: 19.73 (+0.09)
Psychemedics Up 37.0% Since SmarTrend Uptrend Call (PMD)
Comtex SmarTrend(R) - Mon May 09, 1:18PM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ MD) on February 1st, 2016 at $10.20. In approximately 3 months, Psychemedics has returned 36.96% as of today's recent price of $13.97.
PMD: 19.73 (+0.09)
Shares of PMD Up 39.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Apr 29, 1:02PM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ MD) on February 1st, 2016 at $10.20. In approximately 3 months, Psychemedics has returned 39.80% as of today's recent price of $14.26.
PMD: 19.73 (+0.09)
Psychemedics posts 1Q loss
Automated Insights - Tue Apr 26, 5:21PM CDT
ACTON, Mass. (AP) _ Psychemedics Corp. (PMD) on Tuesday reported a first-quarter loss of $23,000, after reporting a profit in the same period a year earlier.
PMD: 19.73 (+0.09)
Psychemedics Corporation Announces Quarterly Results
PR Newswire - Tue Apr 26, 4:45PM CDT
Psychemedics Corporation (NASDAQ: PMD) today announced first quarter financial results for the period ended March 31, 2016. The Company also announced a quarterly dividend of $0.15 per share payable to shareholders of record as of May 6, 2016 to be paid on May 18, 2016. This will be the Company's 79th consecutive quarterly dividend.
PMD: 19.73 (+0.09)
Shares of PMD Up 43.1% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Apr 21, 12:55AM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ MD) on February 1st, 2016 at $10.20. In approximately 3 months, Psychemedics has returned 43.09% as of today's recent price of $14.60.
PMD: 19.73 (+0.09)
Psychemedics posts 4Q profit
Automated Insights - Wed Feb 10, 5:25PM CST
ACTON, Mass. (AP) _ Psychemedics Corp. (PMD) on Wednesday reported fourth-quarter net income of $185,000.
PMD: 19.73 (+0.09)
Psychemedics Corporation Announces Quarterly And Annual Results
PR Newswire - Wed Feb 10, 4:20PM CST
Psychemedics Corporation (NASDAQ MD) today announced fourth quarter and year-end financial results for the period ended December 31, 2015. The Company also announced a quarterly dividend of $0.15 per share payable to shareholders of record as of February 22, 2016 to be paid on March 4, 2016. This will be the Company's 78th consecutive quarterly dividend.
PMD: 19.73 (+0.09)
BUYINS.NET: PMD SqueezeTrigger Price is $10.29. There is $378,290 That Short Sellers Still Need To Cover.
M2 - Tue Feb 09, 10:22AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring PetroMagdalena Energy Corp (NASDAQ MD) in real time and just received an alert that PMD is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 36200 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $10.29. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
PMD: 19.73 (+0.09)
Shares of PMD Down 21.5% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu Jan 28, 10:47AM CST
SmarTrend identified a Downtrend for Psychemedics (NASDAQ MD) on December 29th, 2015 at $10.20. In approximately 1 month, Psychemedics has returned 21.53% as of today's recent price of $8.00.
PMD: 19.73 (+0.09)
North America Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecasts 2016 to 2019
M2 - Tue Jan 26, 4:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/5jg3ps/clinical) has announced the addition of the "Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecasts 2016 to 2019 - North America Version " report to their offering. A market that just keeps on growing. Clinical laboratory testing is positioned to directly benefit from the explosion in biotechnology, especially genomics. A range of dynamic trends are pushing market growth and company valuations. Exciting technical developments especially in the area of molecular diagnostics and pharmacogenomics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. "Clinical Laboratory, Molecular Diagnostic and Genomic Testing Services - 2016 to 2019 North America Version" Features - Data that analysts and planners can use - Hundreds of pages of information including a complete list of Current 2015 United States Medicare Fee Payment Schedules to help sharpen your pricing - Make facilities planning decisions - Forecast demand for new testing regimes or technologies - Make research investment decisions Key Topics Covered: 1. Introduction and Market Definition 2. Market Overview 3. Market Trends 4. Laboratory, Molecular Diagnostics and Genomic Testing Recent Developments 5. Country Market Sizes - North America 6. The Future of the Clinical Laboratory Companies Mentioned - Acibadem Labmed Laboratory - ACM Medical Laboratory - Adicon Clinical Laboratories, Inc. - Alere Inc - American Pathology Partners, Inc. - ARUP Laboratories, Inc. - Ascend Clinical, LLC - Aurora Diagnostics, LLC - Biomnis (France) - Bio-Reference Laboratories, Inc. - Bioscientia Institut fuer Medizinische Diagnostik GmbH - BP Lab - Caris Life Sciences, Inc. - Centrex Clinical Laboratories, Inc. - Clarient, Inc. - Clongen Laboratories LLC - CompuNet Clinical Laboratories, LLC - Diagn?sticos da Am?rica (DASA) - DL Reference Laboratory - Enzo Biochem, Inc. - Exagen Diagnostics, Inc. - Genomic Health, Inc. - Genzyme Corporation - Gribbles Pathology - Integrated Regional Laboratories, Inc. - Predictive Biosciences, Inc. - Psychemedics Corp. - Rosetta Genomics Inc. - Signal Genetics LLC - Solstas Lab Partners - Sonic Healthcare Limited - Spectra Spectra Laboratories, Inc. - The Doctor's Laboratory (Sonic Healthcare U.K.) - Unilabs SA - Vira Cor-Ibt Laboratories For more information visit http://www.researchandmarkets.com/research/5jg3ps/clinical
PMD: 19.73 (+0.09), ALR: 43.24 (-0.43), ARDX: 12.31 (+0.48), GHDX: 28.84 (-0.30), ENZ: 5.13 (-0.07)
39.3% Return Seen to Date on SmarTrend Psychemedics Call (PMD)
Comtex SmarTrend(R) - Wed Sep 21, 1:05PM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ
MD) on July 8th, 2016 at $14.46. In approximately 3 months, Psychemedics has returned 39.35% as of today's recent price of $20.15. PMD: 19.73 (+0.09)
Uptrend Call Working As Psychemedics Stock Rises 37.9% (PMD)
Comtex SmarTrend(R) - Wed Sep 14, 12:44AM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ
MD) on July 8th, 2016 at $14.46. In approximately 2 months, Psychemedics has returned 37.90% as of today's recent price of $19.94. PMD: 19.73 (+0.09)
Psychemedics Corporation Earns Prestigious Recognition for Superior Customer Service
PR Newswire - Tue Sep 13, 4:24PM CDT
Psychemedics Corporation (NASDAQ: PMD), the world's leading and largest hair analysis drug testing company, announced that it has been certified as a Center of Excellence by BenchmarkPortal. The Center of Excellence recognition is one of the most prestigious awards in the customer service and support industry.
PMD: 19.73 (+0.09)
Psychemedics Up 45.2% Since SmarTrend Uptrend Call (PMD)
Comtex SmarTrend(R) - Tue Aug 30, 12:26AM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ
MD) on July 8th, 2016 at $14.46. In approximately 2 months, Psychemedics has returned 45.23% as of today's recent price of $21.00. PMD: 19.73 (+0.09)
48.6% Return Seen to Date on SmarTrend Psychemedics Call (PMD)
Comtex SmarTrend(R) - Mon Aug 22, 12:55PM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ
MD) on July 8th, 2016 at $14.46. In approximately 2 month, Psychemedics has returned 48.62% as of today's recent price of $21.49. PMD: 19.73 (+0.09)
Psychemedics Has Returned 43.3% Since SmarTrend Recommendation (PMD)
Comtex SmarTrend(R) - Fri Aug 05, 12:49AM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ
MD) on July 8th, 2016 at $14.46. In approximately 4 weeks, Psychemedics has returned 43.29% as of today's recent price of $20.72. PMD: 19.73 (+0.09)
Psychemedics Up 24.6% Since SmarTrend Uptrend Call (PMD)
Comtex SmarTrend(R) - Thu Jul 28, 1:38PM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ
MD) on July 8th, 2016 at $14.46. In approximately 3 weeks, Psychemedics has returned 24.55% as of today's recent price of $18.01. PMD: 19.73 (+0.09)
Shares of PMD Up 27.5% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue May 17, 12:49AM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ
MD) on February 1st, 2016 at $10.20. In approximately 4 months, Psychemedics has returned 27.45% as of today's recent price of $13.00. PMD: 19.73 (+0.09)
Psychemedics Up 37.0% Since SmarTrend Uptrend Call (PMD)
Comtex SmarTrend(R) - Mon May 09, 1:18PM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ
MD) on February 1st, 2016 at $10.20. In approximately 3 months, Psychemedics has returned 36.96% as of today's recent price of $13.97. PMD: 19.73 (+0.09)
Shares of PMD Up 39.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Apr 29, 1:02PM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ
MD) on February 1st, 2016 at $10.20. In approximately 3 months, Psychemedics has returned 39.80% as of today's recent price of $14.26. PMD: 19.73 (+0.09)
Psychemedics posts 1Q loss
Automated Insights - Tue Apr 26, 5:21PM CDT
ACTON, Mass. (AP) _ Psychemedics Corp. (PMD) on Tuesday reported a first-quarter loss of $23,000, after reporting a profit in the same period a year earlier.
PMD: 19.73 (+0.09)
Psychemedics Corporation Announces Quarterly Results
PR Newswire - Tue Apr 26, 4:45PM CDT
Psychemedics Corporation (NASDAQ: PMD) today announced first quarter financial results for the period ended March 31, 2016. The Company also announced a quarterly dividend of $0.15 per share payable to shareholders of record as of May 6, 2016 to be paid on May 18, 2016. This will be the Company's 79th consecutive quarterly dividend.
PMD: 19.73 (+0.09)
Shares of PMD Up 43.1% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Apr 21, 12:55AM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ
MD) on February 1st, 2016 at $10.20. In approximately 3 months, Psychemedics has returned 43.09% as of today's recent price of $14.60. PMD: 19.73 (+0.09)
Psychemedics posts 4Q profit
Automated Insights - Wed Feb 10, 5:25PM CST
ACTON, Mass. (AP) _ Psychemedics Corp. (PMD) on Wednesday reported fourth-quarter net income of $185,000.
PMD: 19.73 (+0.09)
Psychemedics Corporation Announces Quarterly And Annual Results
PR Newswire - Wed Feb 10, 4:20PM CST
Psychemedics Corporation (NASDAQ
MD) today announced fourth quarter and year-end financial results for the period ended December 31, 2015. The Company also announced a quarterly dividend of $0.15 per share payable to shareholders of record as of February 22, 2016 to be paid on March 4, 2016. This will be the Company's 78th consecutive quarterly dividend. PMD: 19.73 (+0.09)
BUYINS.NET: PMD SqueezeTrigger Price is $10.29. There is $378,290 That Short Sellers Still Need To Cover.
M2 - Tue Feb 09, 10:22AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring PetroMagdalena Energy Corp (NASDAQ
MD) in real time and just received an alert that PMD is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 36200 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $10.29. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com . PMD: 19.73 (+0.09)
Shares of PMD Down 21.5% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu Jan 28, 10:47AM CST
SmarTrend identified a Downtrend for Psychemedics (NASDAQ
MD) on December 29th, 2015 at $10.20. In approximately 1 month, Psychemedics has returned 21.53% as of today's recent price of $8.00. PMD: 19.73 (+0.09)
North America Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecasts 2016 to 2019
M2 - Tue Jan 26, 4:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/5jg3ps/clinical) has announced the addition of the "Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecasts 2016 to 2019 - North America Version " report to their offering. A market that just keeps on growing. Clinical laboratory testing is positioned to directly benefit from the explosion in biotechnology, especially genomics. A range of dynamic trends are pushing market growth and company valuations. Exciting technical developments especially in the area of molecular diagnostics and pharmacogenomics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. "Clinical Laboratory, Molecular Diagnostic and Genomic Testing Services - 2016 to 2019 North America Version" Features - Data that analysts and planners can use - Hundreds of pages of information including a complete list of Current 2015 United States Medicare Fee Payment Schedules to help sharpen your pricing - Make facilities planning decisions - Forecast demand for new testing regimes or technologies - Make research investment decisions Key Topics Covered: 1. Introduction and Market Definition 2. Market Overview 3. Market Trends 4. Laboratory, Molecular Diagnostics and Genomic Testing Recent Developments 5. Country Market Sizes - North America 6. The Future of the Clinical Laboratory Companies Mentioned - Acibadem Labmed Laboratory - ACM Medical Laboratory - Adicon Clinical Laboratories, Inc. - Alere Inc - American Pathology Partners, Inc. - ARUP Laboratories, Inc. - Ascend Clinical, LLC - Aurora Diagnostics, LLC - Biomnis (France) - Bio-Reference Laboratories, Inc. - Bioscientia Institut fuer Medizinische Diagnostik GmbH - BP Lab - Caris Life Sciences, Inc. - Centrex Clinical Laboratories, Inc. - Clarient, Inc. - Clongen Laboratories LLC - CompuNet Clinical Laboratories, LLC - Diagn?sticos da Am?rica (DASA) - DL Reference Laboratory - Enzo Biochem, Inc. - Exagen Diagnostics, Inc. - Genomic Health, Inc. - Genzyme Corporation - Gribbles Pathology - Integrated Regional Laboratories, Inc. - Predictive Biosciences, Inc. - Psychemedics Corp. - Rosetta Genomics Inc. - Signal Genetics LLC - Solstas Lab Partners - Sonic Healthcare Limited - Spectra Spectra Laboratories, Inc. - The Doctor's Laboratory (Sonic Healthcare U.K.) - Unilabs SA - Vira Cor-Ibt Laboratories For more information visit http://www.researchandmarkets.com/research/5jg3ps/clinical
PMD: 19.73 (+0.09), ALR: 43.24 (-0.43), ARDX: 12.31 (+0.48), GHDX: 28.84 (-0.30), ENZ: 5.13 (-0.07)
